Skip to main content
BioLineRx Ltd. logo

BioLineRx Ltd. — Investor Relations & Filings

Ticker · BLRX ISIN · US09071M2052 LEI · 529900AKIOSC15Y63R18 TA Manufacturing
Open in API
Filings indexed 1,676 across all filing types
Latest filing 2021-09-03 Regulatory Filings
Country IL Israel
Listing TA BLRX

About BioLineRx Ltd.

https://www.biolinerx.com/

BioLineRx Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for oncology and rare diseases. The company leverages its drug development capabilities to advance novel, early-stage therapeutic candidates through the clinical development process toward regulatory approval. Its pipeline consists of treatments, including small molecules, designed to address unmet medical needs and deliver meaningful benefits to patients. BioLineRx also partners with other drug developers to advance their early-stage programs.

Recent filings

Filing Released Lang Actions
424B5
Regulatory Filings
2021-09-03 English
COVER
Regulatory Filings
2021-08-18 English
BioLineRx Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Earnings Release Classification · 100% confidence The document is explicitly titled "BioLineRx Reports Second Quarter 2021 Financial Results and Provides Corporate Update" and contains detailed financial figures for the three and six months ended June 30, 2021, including R&D expenses, G&A expenses, operating loss, and cash flow analysis. This structure is characteristic of a periodic financial report covering a period shorter than a full year. The presence of a conference call announcement immediately following the results summary further confirms this is a results disclosure. Therefore, it aligns best with the definition of an Interim / Quarterly Report (IR). It is not an Earnings Release (ER) because it contains extensive financial tables and detailed commentary, going beyond just key highlights. Q2 2021
2021-08-18 English
BioLineRx Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Report Publication Announcement Classification · 100% confidence The document is a short notification (under 2,000 characters) from BioLine Rx Ltd to the Israel Securities Authority. It explicitly states 'Attached hereto is a report on Second Quarter 2021 Financial Results' and provides a filename for the attachment. Per the 'Menu vs Meal' rule, since this is an announcement of a report rather than the report itself, it is classified as a Report Publication Announcement (RPA). H1 2021
2021-08-18 English
6-K
Regulatory Filings
2021-05-26 English
BioLineRx Reports First Quarter 2021 Financial Results and Provides Corporate Update
Interim / Quarterly Report Classification · 100% confidence The document is a Form 6-K filed with the SEC by BioLineRx Ltd. It contains the company's quarterly financial results, including a press release, condensed consolidated interim financial statements, and an operating and financial review for the period ended March 31, 2021. Since it provides comprehensive financial data and analysis for a quarterly period, it is classified as an Interim/Quarterly Report (IR). Q1 2021
2021-05-26 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.